Resource Logo
NLM AIDSLINE

Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients.




 

Antimicrob Agents Chemother. 1999 Mar;43(3):699-701. Unique Identifier :

The feasibility of rectal administration of didanosine (DDI) was studied in six human immunodeficiency virus-infected patients. After oral intake of a DDI solution (100 mg/m2 of body surface area) combined with an antacid (Maalox), pharmacokinetic parametric values were in accordance with previously published data; the mean +/- standard deviation for terminal half-life was 59.5 +/- 15.0 min, that for peak concentration was 5.2 +/- 3.9 mumol/liter, and that for the area under the time-concentration curve (AUC) was 494 +/- 412 min.mumol/liter. After rectal administration of a similarly prepared DDI solution (100 mg/m2 of body surface area), plasma DDI levels were below the detection limit (0.1 mumol/liter) at all time points in five of the six patients, and in the remaining patient the AUC after rectal application was only 5% of that after oral administration. We conclude that oral administration of DDI cannot be easily replaced by rectal application.

CLINICAL TRIAL JOURNAL ARTICLE Administration, Rectal Adolescence Adult Anti-HIV Agents/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS Area Under Curve Child Didanosine/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS Half-Life Human HIV Infections/*METABOLISM Intestinal Absorption Male Middle Age



 




Information in this article was accurate in August 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.